Market Overview

Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting

Share:
Related
UPDATE: Results from AbbVie's Study of VIEKIRA PAK
Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepat

Enanta Pharmaceuticals (NASDAQ: ENTA) today announced that
additional data from AbbVie's M13-393 (NYSE: ABBV) study, referred to as PEARL-I,
will be presented in an oral presentation at 5:15 p.m. ET today at The
Liver Meeting, the 64th Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD) in Washington, D.C.

In PEARL-I, SVR12 rates of 95% (40/42) in hepatitis C (HCV) GT-1b
treatment-naïve patients and 90% (36/40) among prior null responders
will be presented in this intent-to-treat analysis. Two patients in the
treatment-naive arm did not achieve SVR12 due to loss to follow up. In
the

See full press release

Posted-In: News Guidance FDA Global

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters